206 related articles for article (PubMed ID: 37837788)
21. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
23. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
[TBL] [Abstract][Full Text] [Related]
24. Engineering chimeric antigen receptor T cells for solid tumour therapy.
Liu L; Qu Y; Cheng L; Yoon CW; He P; Monther A; Guo T; Chittle S; Wang Y
Clin Transl Med; 2022 Dec; 12(12):e1141. PubMed ID: 36495108
[TBL] [Abstract][Full Text] [Related]
25. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.
Beavis PA; Slaney CY; Kershaw MH; Gyorki D; Neeson PJ; Darcy PK
Semin Immunol; 2016 Feb; 28(1):64-72. PubMed ID: 26611350
[TBL] [Abstract][Full Text] [Related]
26. CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer.
Mavi AK; Gaur S; Gaur G; Babita ; Kumar N; Kumar U
Cell Signal; 2023 May; 105():110638. PubMed ID: 36822565
[TBL] [Abstract][Full Text] [Related]
27. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer.
Chekmasova AA; Brentjens RJ
Discov Med; 2010 Jan; 9(44):62-70. PubMed ID: 20102688
[TBL] [Abstract][Full Text] [Related]
28. Adoptive cellular therapies: the current landscape.
Rohaan MW; Wilgenhof S; Haanen JBAG
Virchows Arch; 2019 Apr; 474(4):449-461. PubMed ID: 30470934
[TBL] [Abstract][Full Text] [Related]
29. Promises and challenges of adoptive T-cell therapies for solid tumours.
Morotti M; Albukhari A; Alsaadi A; Artibani M; Brenton JD; Curbishley SM; Dong T; Dustin ML; Hu Z; McGranahan N; Miller ML; Santana-Gonzalez L; Seymour LW; Shi T; Van Loo P; Yau C; White H; Wietek N; Church DN; Wedge DC; Ahmed AA
Br J Cancer; 2021 May; 124(11):1759-1776. PubMed ID: 33782566
[TBL] [Abstract][Full Text] [Related]
30. Engineering CAR-T Cells for Improved Function Against Solid Tumors.
Morgan MA; Schambach A
Front Immunol; 2018; 9():2493. PubMed ID: 30420856
[TBL] [Abstract][Full Text] [Related]
31. CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy.
Zhang XW; Wu YS; Xu TM; Cui MH
Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979400
[TBL] [Abstract][Full Text] [Related]
32. Navigating CAR-T cells through the solid-tumour microenvironment.
Hou AJ; Chen LC; Chen YY
Nat Rev Drug Discov; 2021 Jul; 20(7):531-550. PubMed ID: 33972771
[TBL] [Abstract][Full Text] [Related]
33. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
Hiltensperger M; Krackhardt AM
Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
[TBL] [Abstract][Full Text] [Related]
34. Adoptive T cell therapy: Boosting the immune system to fight cancer.
Leon E; Ranganathan R; Savoldo B
Semin Immunol; 2020 Jun; 49():101437. PubMed ID: 33262066
[TBL] [Abstract][Full Text] [Related]
35. Counteracting CAR T cell dysfunction.
Poorebrahim M; Melief J; Pico de Coaña Y; L Wickström S; Cid-Arregui A; Kiessling R
Oncogene; 2021 Jan; 40(2):421-435. PubMed ID: 33168929
[TBL] [Abstract][Full Text] [Related]
36. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
Koneru M; O'Cearbhaill R; Pendharkar S; Spriggs DR; Brentjens RJ
J Transl Med; 2015 Mar; 13():102. PubMed ID: 25890361
[TBL] [Abstract][Full Text] [Related]
37. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
38. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
39. Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.
Noraldeen SAM; Rasulova I; Lalitha R; Hussin F; Alsaab HO; Alawadi AH; Alsaalamy A; Sayyid NH; Alkhafaji AT; Mustafa YF; Shayan SK
Med Oncol; 2023 Oct; 40(11):313. PubMed ID: 37779152
[TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
Mao R; Hussein MS; He Y
Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
